SV2016005305A - Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 - Google Patents
Compuestos heteroaromáticos y su uso como ligandos de dopamina d1Info
- Publication number
- SV2016005305A SV2016005305A SV2016005305A SV2016005305A SV2016005305A SV 2016005305 A SV2016005305 A SV 2016005305A SV 2016005305 A SV2016005305 A SV 2016005305A SV 2016005305 A SV2016005305 A SV 2016005305A SV 2016005305 A SV2016005305 A SV 2016005305A
- Authority
- SV
- El Salvador
- Prior art keywords
- diginates
- dopamine
- compounds
- heteroaromatic compounds
- schizophrenia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA, EN PARTE, COMPUESTOS DE LA FÓRMULA I: (VER FORMULA); Y LAS SALES DE ESTOS ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO; PROCESOS PARA LA PREPARACIÓN DE; INTERMEDIARIOS USADOS EN LA PREPARACIÓN DE; Y COMPOSICIONES QUE CONTIENEN ESTOS COMPUESTOS O SALES, Y SUS USOS PARA TRATAR TRASTORNOS MEDIADOS POR D1 (O ASOCIADOS A D1) QUE INCLUYEN, POR EJEMPLO, ESQUIZOFRENIA (POR EJEMPLO, SUS SÍNTOMAS COGNITIVOS Y NEGATIVOS), TRASTORNO ESQUIZOTÍPICO DE LA PERSONALIDAD, DEFICIENCIA COGNITIVA (POR EJEMPLO, DEFICIENCIA COGNITIVA ASOCIADA A ESQUIZOFRENIA, AD, PD O TRATAMIENTO DE FARMACOTERAPIA), ADHD, ENFERMEDAD DE PARKINSON, ANSIEDAD Y DEPRESIÓN
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984079P | 2014-04-25 | 2014-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2016005305A true SV2016005305A (es) | 2017-07-19 |
Family
ID=53276921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2016005305A SV2016005305A (es) | 2014-04-25 | 2016-10-25 | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |
Country Status (26)
Country | Link |
---|---|
US (2) | US9540352B2 (es) |
EP (1) | EP3134404A1 (es) |
JP (1) | JP6239149B2 (es) |
KR (1) | KR20160142402A (es) |
CN (1) | CN107074843A (es) |
AP (1) | AP2016009512A0 (es) |
AU (1) | AU2015249497A1 (es) |
BR (1) | BR112016023740A2 (es) |
CA (1) | CA2946475A1 (es) |
CL (1) | CL2016002677A1 (es) |
CR (1) | CR20160494A (es) |
CU (1) | CU20160156A7 (es) |
DO (1) | DOP2016000289A (es) |
EA (1) | EA201691788A1 (es) |
IL (1) | IL248132A0 (es) |
MA (1) | MA39914A (es) |
MD (1) | MD20160109A2 (es) |
MX (1) | MX2016013969A (es) |
NI (1) | NI201600161A (es) |
PE (1) | PE20170009A1 (es) |
PH (1) | PH12016501993A1 (es) |
SG (1) | SG11201608468TA (es) |
SV (1) | SV2016005305A (es) |
TN (1) | TN2016000447A1 (es) |
TW (1) | TWI561517B (es) |
WO (1) | WO2015162516A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201691831A1 (ru) * | 2014-04-25 | 2017-02-28 | Пфайзер Инк. | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов |
EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
JP6564394B2 (ja) | 2014-04-28 | 2019-08-21 | ファイザー・インク | 複素環式化合物およびそのドーパミンd1リガンドとしての使用 |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
CN110494432B (zh) | 2016-12-28 | 2022-08-12 | 米尼奥尔克斯治疗有限公司 | 异喹啉化合物,其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63145272A (ja) * | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | 4,5−ジヒドロ−6−(4−置換フエニル)−3(2h)−ピリダジノン誘導体 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US20030013733A1 (en) | 2000-09-22 | 2003-01-16 | Richard Apodaca | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine |
CA2615420A1 (en) * | 2005-07-15 | 2007-01-25 | 4Sc Ag | 2-arylbenzothiazoles and uses thereof |
EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
KR20090064478A (ko) * | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
MX2011005935A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
CA2750051A1 (en) * | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
SG183263A1 (en) * | 2010-02-11 | 2012-09-27 | Univ Vanderbilt | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
JP5860417B2 (ja) * | 2010-03-04 | 2016-02-16 | メルク・シャープ・エンド・ドーム・コーポレイション | カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 |
KR20180032686A (ko) * | 2010-03-24 | 2018-03-30 | 아미텍 테러퓨틱 솔루션즈 인크 | 인산화효소 억제에 유용한 헤테로환 화합물 |
CN102558147B (zh) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
BR112015010412A2 (pt) | 2012-11-08 | 2017-07-11 | Pfizer | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 |
ES2649144T3 (es) | 2012-11-08 | 2018-01-10 | Pfizer Inc. | Compuestos heteroaromáticos y su uso como ligandos de dopamina D1 |
CN102964340B (zh) * | 2012-12-12 | 2015-10-07 | 中国药科大学 | 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂 |
RS59018B1 (sr) | 2013-06-27 | 2019-08-30 | Pfizer | Heteroaromatična jedinjenja i njihova upotreba kao dopamin d1 liganada |
EA201691831A1 (ru) | 2014-04-25 | 2017-02-28 | Пфайзер Инк. | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов |
EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
JP6564394B2 (ja) | 2014-04-28 | 2019-08-21 | ファイザー・インク | 複素環式化合物およびそのドーパミンd1リガンドとしての使用 |
-
2015
- 2015-04-09 JP JP2016564000A patent/JP6239149B2/ja not_active Expired - Fee Related
- 2015-04-09 MX MX2016013969A patent/MX2016013969A/es unknown
- 2015-04-09 PE PE2016002126A patent/PE20170009A1/es not_active Application Discontinuation
- 2015-04-09 CR CR20160494A patent/CR20160494A/es unknown
- 2015-04-09 EP EP15726685.9A patent/EP3134404A1/en not_active Withdrawn
- 2015-04-09 AP AP2016009512A patent/AP2016009512A0/en unknown
- 2015-04-09 CA CA2946475A patent/CA2946475A1/en not_active Abandoned
- 2015-04-09 EA EA201691788A patent/EA201691788A1/ru unknown
- 2015-04-09 SG SG11201608468TA patent/SG11201608468TA/en unknown
- 2015-04-09 MD MDA20160109A patent/MD20160109A2/ro not_active Application Discontinuation
- 2015-04-09 AU AU2015249497A patent/AU2015249497A1/en not_active Abandoned
- 2015-04-09 KR KR1020167032884A patent/KR20160142402A/ko not_active Application Discontinuation
- 2015-04-09 CN CN201580021950.5A patent/CN107074843A/zh active Pending
- 2015-04-09 BR BR112016023740A patent/BR112016023740A2/pt not_active IP Right Cessation
- 2015-04-09 WO PCT/IB2015/052604 patent/WO2015162516A1/en active Application Filing
- 2015-04-09 MA MA039914A patent/MA39914A/fr unknown
- 2015-04-09 TN TN2016000447A patent/TN2016000447A1/en unknown
- 2015-04-22 TW TW104112874A patent/TWI561517B/zh not_active IP Right Cessation
- 2015-04-23 US US14/694,333 patent/US9540352B2/en active Active
-
2016
- 2016-03-22 US US15/077,229 patent/US9850232B2/en active Active
- 2016-09-29 IL IL248132A patent/IL248132A0/en unknown
- 2016-10-07 PH PH12016501993A patent/PH12016501993A1/en unknown
- 2016-10-20 CL CL2016002677A patent/CL2016002677A1/es unknown
- 2016-10-21 NI NI201600161A patent/NI201600161A/es unknown
- 2016-10-24 CU CUP2016000156A patent/CU20160156A7/es unknown
- 2016-10-25 SV SV2016005305A patent/SV2016005305A/es unknown
- 2016-10-25 DO DO2016000289A patent/DOP2016000289A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US9850232B2 (en) | 2017-12-26 |
TWI561517B (en) | 2016-12-11 |
TW201604188A (zh) | 2016-02-01 |
JP6239149B2 (ja) | 2017-11-29 |
NI201600161A (es) | 2016-11-25 |
MX2016013969A (es) | 2017-01-11 |
EA201691788A1 (ru) | 2017-03-31 |
TN2016000447A1 (en) | 2018-04-04 |
CA2946475A1 (en) | 2015-10-29 |
US20160200711A1 (en) | 2016-07-14 |
AP2016009512A0 (en) | 2016-10-31 |
SG11201608468TA (en) | 2016-11-29 |
DOP2016000289A (es) | 2017-02-15 |
PH12016501993A1 (en) | 2017-01-09 |
CN107074843A (zh) | 2017-08-18 |
MD20160109A2 (ro) | 2017-04-30 |
BR112016023740A2 (pt) | 2017-08-15 |
US9540352B2 (en) | 2017-01-10 |
KR20160142402A (ko) | 2016-12-12 |
EP3134404A1 (en) | 2017-03-01 |
AU2015249497A1 (en) | 2016-10-20 |
JP2017513881A (ja) | 2017-06-01 |
IL248132A0 (en) | 2016-11-30 |
PE20170009A1 (es) | 2017-03-17 |
US20150307494A1 (en) | 2015-10-29 |
CU20160156A7 (es) | 2017-02-02 |
MA39914A (fr) | 2017-03-01 |
CL2016002677A1 (es) | 2017-02-10 |
CR20160494A (es) | 2016-12-20 |
WO2015162516A1 (en) | 2015-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2016005306A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
DOP2016000195A (es) | Compuestos | |
SV2016005305A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
SV2018005775A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
UY35129A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
CL2012003178A1 (es) | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2014002847A1 (es) | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. | |
UY36218A (es) | “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1” | |
CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
CL2015003196A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2. | |
DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
CL2016003230A1 (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |